Biocon is an Indian multinational pharmaceutical company founded by Kiran Mazumdar-Shaw in 1978. With its foundation in Bangalore, India, Biocon manufactures generic active pharmaceutical ingredients. They have their name worldwide and export their products to over 120 countries and in markets like the USA and Europe. Biocon manufactures various branded formulations and has its subsidiary in Syngene International Limited (Syngene), which is publicly listed. The business’s beginning was just with the capital of 10,000 INR, but now their net income stands at 100 million USD proving their dedication. Their first product to market was papain, an enzyme found in papaya to prevent beer from turning hazy. Biocon and Syngene employ 9200 people. It has a significant place on the National stock exchange and Bombay stock exchange.
Biocon has an excellent product library and deals in Small molecules, branded formulations, research services, and biologics.
Biocon's portfolio consists of 36 brands across the four therapeutic divisions.
Some of the flagship products from their catalogue includes
BIOMAb EGFR (Nimotuzumab)
BLISTO (Glimepiride + Metformin)
Biocon and Unilever-
In 1989 Unilever took over Biocon Biochemicals Ltd. in Ireland and joined forces with its subsidiary, but in 1998, Unilever agreed to sell its part of shareholding in Biocon to Indian promoters. Thus in 1998, Biocon became an independent entity.
Biocon established Biocon Biopharmaceuticals Pvt. Ltd. (BBPL) in 2003 as a joint venture with the Cuban institute CIMAB to produce and market many MAbs and cancer vaccines.
In 2008, Biocon acquired a majority stake of 70% in AxiCorp GmbH, a German pharmaceutical marketing company.
In 2008, Biocon and IATRICa of the United States declared a strategic partnership to co-develop immunoconjugates for targeted immunotherapy of cancers and infectious conditions.
In 2009, Biocon and Amylin Pharmaceuticals of the United States joined alliances to formulate, market, and manufacture a novel peptide therapeutics for the possible remedy of diabetes.
In January 2018, Sandoz (a Novartis division) announced a global partnership with Biocon to develop, produce, and market various biosimilars in immunology and oncology for patients globally.
1979 - Becomes the first Indian organisation to produce and transport enzymes to the USA and Europe.
1994 - Institutes Syngene International Pvt. Ltd. as a Custom Research Company (CRC).
2003 - Biocon becomes the first corporation globally to produce human insulin on a Pichia expression system.
2014 - Biocon launches the world's first biosimilar drug CANMAb to heal breast cancer.
2016 - Becomes the first Indian company to launch a biosimilar Insulin Glargine pen in Japan.
2019- Annual Greentech Environment Award for Achievements in Environment Management in the Pharmaceutical Sector- 19th Annual Greentech Sustainability Conference.
2018-Chairperson and Managing Director Kiran Mazumdar-Shaw ranked No.2 in Fortune magazine in India’s Most Powerful Women in Business List.
2017-Biocon ranked 09 among Global Biotech Employers for 2017 by Science magazine. The only Asian company to feature in Top 20.
2015- Biocon Foundation wins WHO - India Public Health Champion Award.
2009- Biocon was among the top 20 Indian Companies in Forbes: Best Under A Billion list.
1985- Got the National Award for Best Small Industry by the Government of India.
Invest Yadnya is a company that educates and simplifies the concepts of personal finance for each individual. We have amalgamated technology with financial planning expertise to help an individual meet their financial objectives. We invest time, money, and knowledge to build financial literacy in India.
We offer various products and services including, Personalized Financial Planning, Stock Market Analysis with eBook Subscriptions, Simplest Income Tax Information Bank, Comprehensive Mutual Fund Reviews, and Do-It-Yourself Financial Planning.
Invest Yadnya should be a choice because it offers unbiased and transparent stock analysis reports. Our work is knowledge-based and has specific proprietary methodologies and a stock research framework. We continuously keep updating our data and have the latest information available.
We help our clients do extensive research on 950+ companies, including Biocon fundamental analysis. You can find the latest Biocon stock price on Invest Yadnya. It helps the clients understand the financial position of the company before making any investment decisions. The Biocon stock analysis helps the investors identify the intrinsic worth of the security. Biocon results provide a summary of how the business incurs revenues and expenses. We also offer our clients with the Biocon share price graph.
Invest Yadnya offers numerous resources for Biocon share analysis. With the available Biocon annual report, price chart, ratios, etc., get a detailed analysis of the company. With Invest Yadnya’s available resources, get an overview of the company, both from the qualitative and financial perspective. The investors shall make a viable investment decision depending on your risk profile & other economic factors.
The Biocon research report gives the clients a better understanding of the company’s EPS, Debt-Equity Ratio etc. It helps clients take the first step in choosing which companies to invest in.
Biocon quarterly results & Biocon financial statements help allocate the equity in the Portfolio of an investor to add to its favourable returns.
To find the Biocon stock review, subscribe to our Equity Research and Stock Fundamental Analysis Tool, Stock-O-Meter.
Our website has information about 113 other Pharmaceuticals & Drugs companies that give insight into its financials. Companies include Dr Reddy's Laboratories, Divis Laboratories, Cipla, Sun Pharmaceutical Industries, Aurobindo Pharma, Lupin, Torrent Pharmaceuticals, Cadila Healthcare, Abbott India, Glaxosmithkline Pharmaceuticals & many more.